UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____________ to ____________ Commission File Number 001-34471 CHINA PHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 75- ...

Core Insights - West Pharmaceutical Services, Inc. has launched the West Synchrony Prefillable Syringe (PFS) System, which will be commercially available in January 2026, marking a significant advancement in drug delivery solutions [1][4]. Product Overview - The West Synchrony PFS system is a fully integrated and verified prefillable syringe system designed for biologics and vaccines, providing a comprehensive performance and regulatory data package [3][7]. - This system aims to streamline the design process, accelerate regulatory submissions, and ensure a reliable supply chain for combination products [4][7]. Market Context - Pharmaceutical companies currently face challenges in selecting prefillable syringes due to fragmented approaches, which can lead to delays and increased costs [4]. - The introduction of the West Synchrony PFS system is expected to address these challenges by offering a single-source solution that enhances efficiency in drug development [4][7]. Company Background - West Pharmaceutical Services, Inc. is a leading provider of innovative injectable solutions, generating $2.89 billion in net sales in fiscal year 2024 and delivering over 41 billion components and devices annually [8]. - The company operates with a workforce of 10,000 across 50 sites, including 25 manufacturing facilities worldwide [8].

Core Insights - Defence Therapeutics Inc. is participating in CPHI Worldwide 2025, a major global pharmaceutical trade fair in Frankfurt, Germany from October 28-30, 2025 [1][2] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [6] Event Participation - The company aims to engage with potential partners across the biopharma value chain and connect with the global pharmaceutical community to learn about the latest trends in pharmaceutical manufacturing [2] - Defence Therapeutics is hosting a Meet & Greet event on October 29, 2025, from 4:30-6:30 PM at the Kimpton Hotel in Frankfurt, providing an informal setting for networking and exploring partnership opportunities [3][4] CPHI Overview - CPHI is a leading global pharmaceutical trade show expected to attract over 62,000 visitors and around 2,400 exhibiting companies in 2025, featuring more than 180 international speakers [5]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - SHF Holdings, Inc. (SHFS) increased by 150% to $8.17 - Lithium Americas Corp. (LAC) rose by 69% to $5.18 - Aqua Metals, Inc. (AQMS) gained 50% reaching $6.11 - CleanCore Solutions, Inc. (ZONE) up by 44% at $2.87 - Cyclerion Therapeutics, Inc. (CYCN) increased by 33% to $4.03 - Twin Vee Powercats Co. (VEEE) rose by 17% to $2.92 - Solidion Technology, Inc. (STI) up by 11% at $5.09 - China Pharma Holdings, Inc. (CPHI) increased by 11% to $2.18 - Stardust Power Inc. (SDST) rose by 10% to $3.04 - Aligos Therapeutics, Inc. (ALGS) increased by 7% to $11.03 [3] Premarket Losers - Aytu BioPharma, Inc. (AYTU) decreased by 15% to $2.11 - Professional Diversity Network, Inc. (IPDN) down by 13% to $4.10 - STRATA Skin Sciences, Inc. (SSKN) fell by 10% to $2.31 - Cohu, Inc. (COHU) decreased by 9% to $20.68 - Super League Enterprise, Inc. (SLE) down by 9% to $7.74 - CTW Cayman (CTW) fell by 9% to $2.29 - Fitell Corporation (FTEL) decreased by 8% to $7.70 - Soluna Holdings, Inc. (SLNH) down by 8% to $2.16 - StableX Technologies, Inc. (SBLX) decreased by 5% to $5.22 - Indaptus Therapeutics, Inc. (INDP) down by 5% to $2.95 [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) For the transition period from ____________ to ____________ Commission File Number 001-34471 CHINA PHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 75-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (Address of principal executive offices) (Zip Code) +86- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____________ to ____________ Commission File Number 001-34471 CHINA PHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 75-1564 ...

HAIKOU, China, April 4, 2025 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Tuesday, April 15, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T 401.Th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _____________ Commission file number: 001-34471 China Pharma Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 73-1564807 (State or other juri ...

Core Viewpoint - China Pharma Holdings, Inc. has successfully completed all redemptions under its Convertible Promissory Note agreement, marking a significant improvement in its financial position and commitment to fiscal management [1][2][3] Financial Position - The Convertible Promissory Note was issued on November 17, 2021, with a principal amount of $5,250,000, and has undergone amendments, including an extension of the maturity date to August 19, 2025 [2] - The completion of redemptions reflects the company's proactive measures to fulfill its financial commitments, thereby maintaining investor confidence and operational stability [2][3] Strategic Initiatives - The CEO of China Pharma expressed that the completion of redemptions strengthens the company's financial foundation and supports its strategic initiatives [3] - With the redemptions complete, the company is positioned to pursue growth objectives and deliver long-term value to stockholders [3] Company Overview - China Pharma Holdings, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and marketing a diversified portfolio of products targeting high incidence and high mortality conditions in China, such as cardiovascular, CNS, infectious, and digestive diseases [4] - The company operates a cost-effective business model driven by market demand and has a nationwide distribution network across major cities and provinces in China [4]

HAIKOU, China, Dec. 13, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (the "SEC") under which the Company may offer and sell from time to time shares of common stock, par value $0.001 per share (the "Common Stock"), with an aggregate offering price of up to $600,000 (the "Financing").The shares will be offe ...